Photo of Jacob D. Soumerai,  MD

Jacob D. Soumerai, MD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 724-4000


jsoumerai@mgh.harvard.edu

Jacob D. Soumerai, MD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Clinical Instructor, Medicine, Harvard Medical School
  • Clinical Investigator in Lymphoma, Medicine, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Publications

Powered by Harvard Catalyst
  • Soumerai JD, Zelenetz AD, Moskowitz CH, Palomba ML, Hamlin PA, Noy A, Straus DJ, Moskowitz AJ, Younes A, Matasar MJ, Horwitz SM, Portlock CS, Konner JA, Gounder MM, Hyman DM, Voss MH, Fury MG, Gajria D, Carvajal RD, Ho AL, Beumer JH, Kiesel B, Zhang Z, Chen A, Little RF, Jarjies C, Dang TO, France F, Mishra N, Gerecitano JF. The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. Clin Cancer Res 2017. PubMed
  • Bledsoe JR, Redd RA, Hasserjian RP, Soumerai JD, Nishino HT, Boyer DF, Ferry JA, Zukerberg LR, Harris NL, Abramson JS, Sohani AR. The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome. Am J Hematol 2016; 91:E436-41. PubMed
  • Soumerai JD, Sohani AR, Abramson JS. Diagnosis and management of Castleman disease. Cancer Control 2014; 21:266-78. PubMed
  • Soumerai JD, Hellmann MD, Feng Y, Sohani AR, Toomey CE, Barnes JA, Takvorian RW, Neuberg D, Hochberg EP, Abramson JS. Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease. Leuk Lymphoma 2014; 55:538-43. PubMed
  • Treon SP, Soumerai JD, Hunter ZR, Patterson CJ, Ioakimidis L, Kahl B, Boxer M. Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab. Blood 2011; 118:276-81. PubMed
  • Treon SP, Ioakimidis L, Soumerai JD, Patterson CJ, Sheehy P, Nelson M, Willen M, Matous J, Mattern J, Diener JG, Keogh GP, Myers TJ, Boral A, Birner A, Esseltine DL, Ghobrial IM. Primary therapy of Waldenstr旦m macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol 2009; 27:3830-5. PubMed
  • Treon SP,Branagan AR,Ioakimidis L,Soumerai JD,Patterson CJ,Turnbull B,Wasi P,Emmanouilides C,Frankel SR,Lister A,Morel P,Matous J,Gregory SA,Kimby E. Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Blood 2008; 113:3673-8. PubMed
  • Leleu X,Hunter ZR,Xu L,Roccaro AM,Moreau AS,Santos DD,Hatjiharissi E,Bakthavachalam V,Adamia S,Ho AW,Soumerai J,Patterson CJ,Manning RJ,Hamilton S,Verselis S,Fox E,Carrasco R,Ghobrial IM,Treon SP. Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia. British Journal of Haematology 2009; 145:59-63. PubMed
  • Leleu X,Tamburini J,Roccaro A,Morel P,Soumerai J,Levy V,Wemeau M,Balkaran S,Poulain S,Hunter ZR,Ghobrial IM,Treon SP,Leblond V. Balancing risk versus benefit in the treatment of Waldenstrom's Macroglobulinemia patients with nucleoside analogue-based therapy. Clin Lymphoma Myeloma 2009; 9:71-3. PubMed
  • Ioakimidis L,Patterson CJ,Hunter ZR,Soumerai JD,Manning RJ,Turnbull B,Sheehy P,Treon SP. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2009; 9:62-6. PubMed
  • Leleu X,Xu L,Jia X,Sacco A,Farag M,Hunter ZR,Moreau AS,Ngo HT,Hatjiharissi E,Ho AW,Santos DD,Adamia S,O'Connor K,Ciccarelli B,Soumerai J,Manning RJ,Patterson CJ,Roccaro AM,Ghobrial IM,Treon SP. Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. Blood 2008; 113:626-34. PubMed
  • Leleu X,Soumerai J,Roccaro A,Hatjiharissi E,Hunter ZR,Manning R,Ciccarelli BT,Sacco A,Ioakimidis L,Adamia S,Moreau AS,Patterson CJ,Ghobrial IM,Treon SP. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. J Clin Oncol 2008; 27:250-5. PubMed
  • Treon SP,Soumerai JD,Branagan AR,Hunter ZR,Patterson CJ,Ioakimidis L,Chu L,Musto P,Baron AD,Nunnink JC,Kash JJ,Terjanian TO,Hyman PM,Nawfel EL,Sharon DJ,Munshi NC,Anderson KC. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res 2009; 15:355-60. PubMed
  • Treon SP,Soumerai JD,Branagan AR,Hunter ZR,Patterson CJ,Ioakimidis L,Briccetti FM,Pasmantier M,Zimbler H,Cooper RB,Moore M,Hill J 2nd,Rauch A,Garbo L,Chu L,Chua C,Nantel SH,Lovett DR,Boedeker H,Sonneborn H,Howard J,Musto P,Ciccarelli BT,Hatjiharissi E,Anderson KC. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 2008; 112:4452-7. PubMed
  • Ho AW, Hatjiharissi E, Ciccarelli BT, Branagan AR, Hunter ZR, Leleu X, Tournilhac O, Xu L, O'Connor K, Manning RJ, Santos DD, Chemaly M, Patterson CJ, Soumerai JD, Munshi NC, McEarchern JA, Law CL, Grewal IS, Treon SP. CD27-CD70 interactions in the pathogenesis of Waldenstrom's Macroglobulinemia. Blood 2008; 112:4683-9. PubMed
  • Moreau AS,Jia X,Patterson CJ,Roccaro AM,Xu L,Sacco A,O'Connor K,Soumerai J,Ngo HT,Hatjiharissi E,Hunter ZR,Ciccarelli B,Manning R,Ghobrial IM,Leleu X,Treon SP. The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia. British Journal of Haematology 2008; 142:775-85. PubMed
  • Treon SP, Hatjiharissi E, Leleu X, Moreau AS, Roccaro A, Hunter ZR, Soumerai JD, Ciccarelli B, Xu L, Sacco A, Ngo HT, Jia X, Yang C, Adamia S, Branagan AR, Ho AW, Santos DD, Tournilhac O, Manning RJ, Leduc R, O'Connor K, Nelson M, Patterson CJ, Ghobrial I. Novel agents in the treatment of Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2007; 7 Suppl 5:S199-206. PubMed
  • Leleu X, O'Connor K, Ho AW, Santos DD, Manning R, Xu L, Hatjiharissi E, Moreau AS, Branagan AR, Hunter ZR, Dimmock EA, Soumerai J, Patterson C, Ghobrial I, Treon SP. Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia. Am J Hematol 2006; 82:83-4. PubMed
Hide